CTOs on the Move

Immunocellular Therapeutics (Fka: Optical Molecu

www.imuc.com

 
Immunocellular Therapeutics Ltd (Fka: Optical Molecular Imaging Inc) is a Woodland Hills, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.imuc.com
  • 21900 Burbank Blvd Fl 3
    Woodland Hills, CA USA 91367
  • Phone: 818.992.2907

Executives

Name Title Contact Details

Similar Companies

Nonlethal Technologies

Nonlethal Technologies, Inc is a Homer City, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Batu Biologics

Batu Biologics is a biotechnology-based pharmaceutical company focused on the development and commercialization of novel therapies that target the “Achilles Heel of Cancer:” the tumor blood vessels. Batu’s flagship therapeutic, ValloVax™, is an angiogenesis targeting cancer vaccine in the late stages of preclinical development. Batu Biologics plans to file an Investigational New Drug (IND) application for ValloVax in Q1 of 2015, seeking clinical approval to treat patients with lung cancer.

Socati

Socati is the most advanced producer of THC-free full spectrum hemp. Purpose built for CBD infused products at global manufacturing scale, we combine expertise in seed genetics, proprietary extraction techniques and the most efficient purification systems available today. By integrating the entire supply chain, Socati is your partner in delivering to one of the most lucrative new product categories in history - non-psychoactive cannabinoid infusion.

Inipharm

At Inipharm, we`re building on novel insights and applying our chemistry expertise to develop therapies for patients with liver disease. Inipharm`s lead program is focused on small-molecules to target the activity of HSD17B13, a highly validated, genetically defined target for multiple severe liver and related diseases.

Celladon

Celladon is a privately held biotechnology company founded with the goal of developing molecular therapies for cardiovascular diseases. Breakthroughs in the basic understanding of the cardiovascular networks combined with powerful new technologies have provided the foundation for new, rational, and technologically sophisticated approaches to cardiovascular treatments. Our first product candidate is designed to target the key enzyme deficiency in advanced heart failure which regulates calcium cycling and contractility in heart muscle cells.